文献速递淋巴瘤

EORTC QLQ-CLL17 问卷用于慢性淋巴细胞白血病患者健康相关生活质量评估的国际验证

International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemia.
PubMed 文献 · Br J Haematol · 2022-03-07

这项由欧洲癌症研究与治疗组织(EORTC)开展的国际研究,在来自12个国家的341例慢性淋巴细胞白血病(CLL)患者中检验了新开发的EORTC QLQ-CLL17问卷的心理测量学特性。问卷包含17个条目、三个量表,完成平均需8分钟,重测信度和聚合效度良好,并能区分ECOG体能状态0分与1-3分的患者。

要点

  • 30%-66%的CLL患者报告了肌肉酸痛、乏力及对健康的担忧等症状和/或忧虑。
  • QLQ-CLL17的17个条目在症状负担、身体状况/疲乏、对健康和功能的担忧/恐惧三个量表上拟合可接受至良好。
  • 问卷完成平均需8分钟,重测信度和聚合效度得到验证,可区分ECOG 0分与1-3分患者。

核心结论

  • 新开发的EORTC QLQ-CLL17将提高CLL患者健康相关生活质量评估的敏感性,在临床研究和实践中实施有助于生成独特的临床相关数据以更好地指导CLL治疗决策。

研究设计与样本

  • 欧洲癌症研究与治疗组织(EORTC)开展的国际研究,纳入来自12个国家的341例CLL患者,完成QLQ-C30、QLQ-CLL17及一份汇报问卷,并从病历记录社会人口学和临床数据。

主要发现

  • 30%-66%的患者报告了症状和/或忧虑,如肌肉酸痛、缺乏精力及对健康的担忧/恐惧。
  • 验证性因子分析显示17个条目在三个量表(症状负担、身体状况/疲乏、对健康和功能的担忧/恐惧)上的拟合为可接受至良好。
  • 问卷完成平均需8分钟,重测信度和聚合效度得到验证。
  • QLQ-CLL17可区分ECOG体能状态0分与1-3分的患者(p值均<0.01且具有临床相关性)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Selecting the most appropriate chronic lymphocytic leukaemia (CLL) treatment is challenging. Patient-reported health-related quality of life (HRQoL) is therefore a critical aspect to consider. This international study by the European Organization for Research and Treatment of Cancer (EORTC) tested the psychometric properties of a newly developed measure for CLL patients: the EORTC QLQ-CLL17 to supplement the core questionnaire (EORTC QLQ-C30). Patients with CLL (n = 341) from 12 countries completed the QLQ-C30, QLQ-CLL17 and a debriefing questionnaire. Sociodemographic and clinical data were recorded from medical records. A high percentage (30%-66%) reported symptoms and/or worries (e.g. aches/pains in muscles, lack of energy and worry/fears about health). Confirmatory factor analysis showed an acceptable to good fit of the 17 items on the three scales (i.e. symptom burden, physical condition/fatigue and worries/fears about health and functioning). Completion took on average 8 min. Test-retest and convergent validity was demonstrated. The QLQ-CLL17 differentiated between patients with an Eastern Cooperative Oncology group (ECOG) performance of 0 versus 1-3 (p's < 0.01 and clinically relevant). The newly developed EORTC QLQ-CLL17 will increase sensitivity of HRQoL assessment in patients with CLL. Implementation of this questionnaire both in clinical research and practice will help to generate unique clinically relevant data to better inform CLL treatment decision-making.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Oerlemans S, Efficace F, Kieffer JM, et al. International validation of the EORTC QLQ-CLL17 questionnaire for assessment of health-related quality of life for patients with chronic lymphocytic leukaemia. Br J Haematol. 2022. PMID: 35255152. doi:10.1111/bjh.18072

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。